A detailed history of Great West Life Assurance CO transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 3,351 shares of AXSM stock, worth $319,886. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,351
Previous 7,599 55.9%
Holding current value
$319,886
Previous $611,000 50.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$78.93 - $95.84 $335,294 - $407,128
-4,248 Reduced 55.9%
3,351 $301,000
Q2 2024

Aug 12, 2024

BUY
$65.72 - $80.5 $15,049 - $18,434
229 Added 3.11%
7,599 $611,000
Q1 2024

May 13, 2024

BUY
$69.39 - $97.64 $295,462 - $415,751
4,258 Added 136.83%
7,370 $588,000
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $117,725 - $139,757
1,700 Added 120.4%
3,112 $217,000
Q2 2023

Aug 10, 2023

SELL
$58.41 - $90.35 $7,534 - $11,655
-129 Reduced 8.37%
1,412 $102,000
Q3 2022

Nov 01, 2022

BUY
$36.06 - $69.85 $55,568 - $107,638
1,541 New
1,541 $69,000
Q2 2021

Aug 11, 2021

SELL
$50.63 - $73.5 $26,023 - $37,779
-514 Reduced 25.01%
1,541 $104,000
Q3 2020

Nov 17, 2020

SELL
$68.34 - $85.84 $98,751 - $124,038
-1,445 Reduced 41.29%
2,055 $146,000
Q3 2020

Nov 13, 2020

BUY
$68.34 - $85.84 $98,751 - $124,038
1,445 Added 70.32%
3,500 $249,000
Q2 2020

Aug 17, 2020

BUY
$49.87 - $98.69 $22,192 - $43,917
445 Added 27.64%
2,055 $168,000
Q4 2019

Feb 11, 2020

BUY
$16.71 - $106.24 $26,903 - $171,046
1,610 New
1,610 $166,000
Q3 2019

Oct 25, 2019

SELL
$20.24 - $29.16 $61,428 - $88,500
-3,035 Closed
0 $0
Q2 2019

Jul 31, 2019

BUY
$13.46 - $25.75 $40,851 - $78,151
3,035 New
3,035 $0

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $4.09B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.